Aptevo Therapeutics Inc.

13F holders, Q3 2024 (September 30)
19holders +1
6new positions
5sold out
2famous investors
$0.18avg. 13F price*

At the end of Q3 2024, 19 institutions reported holding Aptevo Therapeutics Inc. in their 13F filings, up 1 from Q2 2024. 6 opened new positions and 5 sold out. The largest holders were Hudson Bay Capital Management LP ($168K), Citadel Advisors ($20K) and Virtu Financial LLC ($8K). 2 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).

Company
Aptevo Therapeutics Inc.
CUSIP
03835L306
Latest filing quarter
Q3 2024

History

Number of 13F holders

05101520 Q1 2024: 10Q1 2024Q2 2024: 18Q2 2024Q3 2024: 19Q3 2024

Total Exit/New Position Q2 2024 → Q3 2024

InstitutionsTotal Value
New Positions6$37K
Exits5$388K

All 13F filers, Q2 2024 → Q3 2024: 709,396 shares bought and 1,389,827 shares sold, net −680,431 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 19 holders

Hudson Bay Capital Management LP 0.00% Add +87.1% 935,552 $168K
Citadel Advisors 0.00% New 111,632 $20K
Virtu Financial LLC 0.00% Add +141.3% 41,967 $8K
Geode Capital Management, LLC 0.00% Add +125.3% 43,684 $8K
Renaissance Technologies 0.00% New 36,575 $7K
Two Sigma Securities, LLC 0.00% New 28,020 $5K
HRT Financial LP 0.00% Reduce -8.0% 28,116 $5K
Tower Research Capital LLC (TRC) 0.00% Add +224.0% 25,069 $5K
Jane Street Group, LLC 0.00% New 17,218 $3K
Two Sigma Investments, LP 0.00% New 14,195 $3K
BlackRock, Inc. 0.00% — 888 $160
Morgan Stanley 0.00% No change 194 $35
Bank of America Corp. 0.00% Reduce -51.9% 77 $14
JPMorgan Chase & Co. 0.00% No change 43 $8
Osaic Holdings, Inc. 0.00% No change 45 $8
Wells Fargo & Company 0.00% No change 33 $6
PNC Financial Services Group, Inc. 0.00% No change 3 $1
UBS Group AG 0.00% Reduce -100.0% 1 $0
Truvestments Capital LLC 0.00% New 2 $0

"% of holder's portfolio" is APTEVO THERAPEUTICS INC's weight in each manager's 13F, not the share of Aptevo Therapeutics Inc. the manager owns.